#United States #New York #Anixa Biosciences #Clinical Trials #Cancer Immunotherapy

Anixa Biosciences' Commitment to Cancer Treatment

Anixa Biosciences, Inc., a key player in biotechnology devoted to cancer treatment and prevention, is gearing up to showcase its innovative underwater immunotherapy programs at an esteemed symposium hosted by the New York Academy of Sciences. Slated for June 22-23, 2026, at the Memorial Sloan Kettering Cancer Center in New York City, this event, titled the Frontiers in Cancer Immunotherapy symposium, will gather leading figures in cancer research, physicians, and industry innovators.

Highlighting Clinical Stage Programs

Anixa’s two notable immunotherapy programs include an ovarian cancer CAR-T therapy, known as lira-cel, and a breast cancer vaccine that has successfully completed its Phase 1 clinical trial. The ovarian cancer therapy, developed in an ongoing Phase 1 clinical trial, aims to target the follicle-stimulating hormone receptor specifically expressed in cells associated with ovarian cancer, optimizing treatment delivery while minimizing damage to healthy cells. This targeted approach exemplifies Anixa's commitment to advancing novel cancer therapies.

The breast cancer vaccine, on the other hand, has shown promising results, with all major primary endpoints achieved, as well as a substantial immune response in 74% of trial participants. The confidence surrounding these findings reflects the rigorous scientific inquiry and collaborative efforts with premier cancer research institutions involved in these studies.

Collaborations with Renowned Institutions

Both therapeutic programs at Anixa are propelled by strategic collaborations with notable institutions such as the Moffitt Cancer Center and Cleveland Clinic. These alliances provide a robust foundation for Anixa to further explore and develop advanced treatment options. At the symposium, Dr. Pamela D. Garzone, Chief Development Officer at Anixa, will present the intricacies of the lira-cel trial, alongside multiple collaborations which include experienced investigators from several institutions. The interdisciplinary teamwork demonstrates an extensive network working towards shared goals in cancer therapy advancement.

Dr. Emily Esakov Rhoades, the FDA/IND Trial Program Manager from the Cleveland Clinic Cancer Institute, will also deliver a presentation on the breast cancer vaccine findings, shedding light on the scientific progress made and the implications these results could have on future treatment protocols.

The Future of Cancer Immunotherapy

The Frontiers in Cancer Immunotherapy symposium serves as a vital platform for discussing innovative ideas and therapeutic advancements in cancer care. Topics of focus include cancer vaccines, bispecific antibody approaches, modulating the tumor microenvironment, and leveraging AI in drug discovery. Each presentation aims to unravel new methods for combating cancer's complex and evolving nature.

Anixa's achievements in the realm of oncology highlight the potential of immunotherapy as a revolutionary tool against cancer. As these programs progress, the company plans on making strides in ensuring that advanced and effective treatments are made available to patients worldwide.

Dr. Amit Kumar, Anixa's Chairman and CEO, emphasizes, "Participation in this symposium is an essential step in showcasing our ongoing advancements and the collaborations that are vital for enhancing our therapies. The significance of our CAR-T therapy and breast cancer vaccine stands not only in their clinical progress but also their potential to reshape cancer treatment paradigms."

With ongoing trials and promising results, Anixa Biosciences is at the forefront, steering the charge in educational efforts, innovations, and partnerships focused on making cancer a more manageable and preventable disease.